71298-1 71298-2
Scientist.com Supplier
KIR2DL3, Fc fusion, Biotin-labeled (Human) Recombinant
BPS Bioscience
DESCRIPTION
Human KIR2DL3, also known as Killer cell immunoglobulin-like receptor 2DL3, KIR2DS5 and KIRCL23. GenBank Accession No. NM_015868. a.a. 22-245 fused at the C terminus to the Fc portion of human IgG1 followed by a C-termina Avi-tag™ and expressed in a HEK293 cell expression system. MW=53 kDa This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. This protein runs at a higher MW due to glycosylation.
DETAILS
- Aa: 22-245
- Mw: 53 kDa
- Tags: C-terminal Fc fusion (Human IgG1), C-terminal Avi-tag™
- Format: Aqueous buffer solution
- Genbank: NM_015868
- Species: Human
- Uniprot: P43628
- Shiptemp: -80°C (dry ice)
- Synonyms: Killer cell immunoglobulin-like receptor 2DL3, KIR2DS5 and KIRCL23
- Warnings: Avoid freeze/thaw cycles.
- Category: Immunotherapy/Protein
- References: 1. Moesta, A, et al., Immunology. 2008 Mar; 180(6):3969-3979. 2. Maenaka, K., et al., Structure. 1999 Jan; 7(4) : 391-398.
- Description: Human KIR2DL3, also known as Killer cell immunoglobulin-like receptor 2DL3, KIR2DS5 and KIRCL23. GenBank Accession No. NM_015868. a.a. 22-245 fused at the C terminus to the Fc portion of human IgG1 followed by a C-termina Avi-tag™ and expressed in a HEK293 cell expression system. MW=53 kDa This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. This protein runs at a higher MW due to glycosylation.
- Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
- Unspsc Code: 12352202
- Unspsc Name: Proteins
- Applications: Useful as an antigen and in protein binding studies.
- Product Type: Protein
- Biosafety Level: Not applicable (BSL-1)
- Related Products: 72309, 79572, 79512
- Storage Stability: Stable for at least 12 months at -80°C. Avoid freeze/thaw cycles. Store diluted antibody with carrier protein (BSA 0.1 - 0.5%) at 4°C, stable for 2 weeks.
- Scientific Category: Immunotherapy